North America Antibody Drug Conjugates Market Size and Forecast (2021 - 2031)
The North America Antibody Drug Conjugates (ADC) Market is projected to grow significantly, reaching approximately US$ 20,332.5 million by 2031, up from US$ 4,432.3 million in 2023, reflecting a compound annual growth rate (CAGR) of 21.0% from 2023 to 2031.
Executive Summary and Market Analysis
The ADC market in North America, which includes the United States, Canada, and Mexico, is experiencing robust growth primarily due to the rising incidence of cancer in the region. The demand for effective and targeted cancer therapies has led to increased research and development efforts, resulting in a promising pipeline of next-generation ADC products. The United States dominates the market, supported by its advanced healthcare infrastructure, a strong presence of pharmaceutical products, and a high rate of approvals from regulatory bodies like the FDA. Canada and Mexico are also contributing to market expansion through increased healthcare investments and improved access to cancer treatments. The growing awareness of the benefits of novel ADCs in enhancing treatment precision and minimizing side effects further supports market growth. Additionally, strategic mergers, partnerships, and collaborations among leading biotech and pharmaceutical companies are fostering innovation and expanding the clinical applications of ADCs, thereby driving the overall growth of the North American ADC market.
Strategic Insights
Market Segmentation Analysis
Strategic investments such as mergers, acquisitions, partnerships, and collaborations among key players in the ADC market are crucial for its growth and development. These strategies allow companies to combine resources, share expertise, and leverage complementary strengths to enhance their competitive position in a rapidly evolving market. ADCs are gaining attention for their ability to selectively target and destroy cancer cells while sparing healthy tissues, thus reducing side effects. Consequently, major pharmaceutical and biotechnology firms are increasingly forming strategic alliances to expedite the development and commercialization of ADCs.
As competition intensifies, companies are looking to acquire or merge with firms that possess promising ADC technologies or candidates in their pipelines. For example, larger pharmaceutical companies often acquire smaller biotech firms specializing in ADC development to quickly integrate advanced technologies into their product lines. Such acquisitions enhance the acquirer's portfolio and provide access to innovative linker technologies, payloads, and targeting mechanisms that can improve therapeutic efficacy and safety. Notable recent transactions include GlycoMimetics, Inc.'s acquisition of Crescent Biopharma, Inc. in October 2024, and Johnson & Johnson's acquisition of Ambrx Biopharma, Inc. in March 2024.
The competitive landscape of the ADC market is characterized by high activity from key players engaging in strategic investments, which fosters innovation and differentiation as companies strive to establish market leadership. The influx of capital into oncology attracts new entrants, creating a vibrant ecosystem that encourages innovative ideas. Overall, strategic investments through mergers, acquisitions, partnerships, and collaborations are pivotal in driving the growth of the ADC market, enhancing product portfolios, improving manufacturing processes, and fostering innovation to develop effective and targeted cancer therapies.
Country Insights
The North America ADC market is segmented by country into the United States, Canada, and Mexico, with the United States holding the largest market share in 2023. The US has seen the highest number of ADC approvals, with numerous products in the pipeline utilizing advanced conjugate and linker technologies, potent payloads, and new antigen targets. According to FDA data from May 2021, there were 113 clinical trials for 77 novel ADCs targeting over 40 different antigens. The FDA has approved several ADCs for various cancer indications, including Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep. In September 2021, the FDA expedited the approval of Tivdak (tisotumab vedotin-tftv) for recurrent or metastatic cervical cancer. Furthermore, in 2023, AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) received regulatory approval in the US for treating HR-positive and HER2-negative locally advanced or metastatic breast cancer with specific biomarker alterations. The ongoing expansion activities by companies in the ADC market in the US further bolster market growth.
Company Profiles
Key players in the North America ADC market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to deliver innovative products and increase their market share.
Executive Summary and Market Analysis
The ADC market in North America, which includes the United States, Canada, and Mexico, is experiencing robust growth primarily due to the rising incidence of cancer in the region. The demand for effective and targeted cancer therapies has led to increased research and development efforts, resulting in a promising pipeline of next-generation ADC products. The United States dominates the market, supported by its advanced healthcare infrastructure, a strong presence of pharmaceutical products, and a high rate of approvals from regulatory bodies like the FDA. Canada and Mexico are also contributing to market expansion through increased healthcare investments and improved access to cancer treatments. The growing awareness of the benefits of novel ADCs in enhancing treatment precision and minimizing side effects further supports market growth. Additionally, strategic mergers, partnerships, and collaborations among leading biotech and pharmaceutical companies are fostering innovation and expanding the clinical applications of ADCs, thereby driving the overall growth of the North American ADC market.
Strategic Insights
Market Segmentation Analysis
- By Technology: The market is divided into Cleavable Linker and Non-cleavable Linker, with Cleavable Linker holding the largest market share in 2023.
- By Application: The ADC market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others, with Breast Cancer leading in market share in 2023.
- By Target: The market is categorized into HER2, CD22, CD30, and Others, with HER2 being the most significant segment in 2023.
- By Distribution Channel: The market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies, with Retail Pharmacies holding the largest share in 2023.
Strategic investments such as mergers, acquisitions, partnerships, and collaborations among key players in the ADC market are crucial for its growth and development. These strategies allow companies to combine resources, share expertise, and leverage complementary strengths to enhance their competitive position in a rapidly evolving market. ADCs are gaining attention for their ability to selectively target and destroy cancer cells while sparing healthy tissues, thus reducing side effects. Consequently, major pharmaceutical and biotechnology firms are increasingly forming strategic alliances to expedite the development and commercialization of ADCs.
As competition intensifies, companies are looking to acquire or merge with firms that possess promising ADC technologies or candidates in their pipelines. For example, larger pharmaceutical companies often acquire smaller biotech firms specializing in ADC development to quickly integrate advanced technologies into their product lines. Such acquisitions enhance the acquirer's portfolio and provide access to innovative linker technologies, payloads, and targeting mechanisms that can improve therapeutic efficacy and safety. Notable recent transactions include GlycoMimetics, Inc.'s acquisition of Crescent Biopharma, Inc. in October 2024, and Johnson & Johnson's acquisition of Ambrx Biopharma, Inc. in March 2024.
The competitive landscape of the ADC market is characterized by high activity from key players engaging in strategic investments, which fosters innovation and differentiation as companies strive to establish market leadership. The influx of capital into oncology attracts new entrants, creating a vibrant ecosystem that encourages innovative ideas. Overall, strategic investments through mergers, acquisitions, partnerships, and collaborations are pivotal in driving the growth of the ADC market, enhancing product portfolios, improving manufacturing processes, and fostering innovation to develop effective and targeted cancer therapies.
Country Insights
The North America ADC market is segmented by country into the United States, Canada, and Mexico, with the United States holding the largest market share in 2023. The US has seen the highest number of ADC approvals, with numerous products in the pipeline utilizing advanced conjugate and linker technologies, potent payloads, and new antigen targets. According to FDA data from May 2021, there were 113 clinical trials for 77 novel ADCs targeting over 40 different antigens. The FDA has approved several ADCs for various cancer indications, including Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep. In September 2021, the FDA expedited the approval of Tivdak (tisotumab vedotin-tftv) for recurrent or metastatic cervical cancer. Furthermore, in 2023, AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) received regulatory approval in the US for treating HR-positive and HER2-negative locally advanced or metastatic breast cancer with specific biomarker alterations. The ongoing expansion activities by companies in the ADC market in the US further bolster market growth.
Company Profiles
Key players in the North America ADC market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to deliver innovative products and increase their market share.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTIBODY DRUG CONJUGATES MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Ecosystem Analysis
4.2.1 Raw Materials and Sourcing
4.2.2 Manufacturing Processes
4.2.3 Regulatory Compliance
4.2.4 Distribution and Logistics
4.2.5 List of Vendors in the Value Chain
5. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTIBODY DRUG CONJUGATES MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
6.2 North America Antibody Drug Conjugates Market Forecast and Analysis
7. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TECHNOLOGY
7.1 Cleavable Linker
7.1.1 Overview
7.1.2 Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Non-cleavable Linker
7.2.1 Overview
7.2.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY APPLICATION
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Brain Cancer
8.2.1 Overview
8.2.2 Brain Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Ovarian Cancer
8.4.1 Overview
8.4.2 Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Lung Cancer
8.5.1 Overview
8.5.2 Lung Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TARGET
9.1 HER2
9.1.1 Overview
9.1.2 HER2: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 CD22
9.2.1 Overview
9.2.2 CD22: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 CD30
9.3.1 Overview
9.3.2 CD30: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
10.1 Retail Pharmacies
10.1.1 Overview
10.1.2 Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Hospital Pharmacies
10.2.1 Overview
10.2.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET - COUNTRY ANALYSIS
11.1 North America
11.1.1 North America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.1.1 North America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.2.2 United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 United States: North America Antibody Drug Conjugates Market Share - by Technology
11.1.2.2.2 United States: North America Antibody Drug Conjugates Market Share - by Application
11.1.2.2.3 United States: North America Antibody Drug Conjugates Market Share - by Target
11.1.2.2.4 United States: North America Antibody Drug Conjugates Market Share - by Distribution Channel
11.2.3.3 Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Canada: North America Antibody Drug Conjugates Market Share - by Technology
11.2.3.3.2 Canada: North America Antibody Drug Conjugates Market Share - by Application
11.2.3.3.3 Canada: North America Antibody Drug Conjugates Market Share - by Target
11.2.3.3.4 Canada: North America Antibody Drug Conjugates Market Share - by Distribution Channel
11.3.4.4 Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Mexico: North America Antibody Drug Conjugates Market Share - by Technology
11.3.4.4.2 Mexico: North America Antibody Drug Conjugates Market Share - by Application
11.3.4.4.3 Mexico: North America Antibody Drug Conjugates Market Share - by Target
11.3.4.4.4 Mexico: North America Antibody Drug Conjugates Market Share - by Distribution Channel
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 GSK Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Co
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Astellas Pharma Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AbbVie Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Merck KGaA
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Gilead Sciences Inc
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 BioNTech SE
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
14.13 Daiichi Sankyo Co Ltd
14.13.1 Key Facts
14.13.2 Business Description
14.13.3 Products and Services
14.13.4 Financial Overview
14.13.5 SWOT Analysis
14.13.6 Key Developments
14.14 RemeGen Co Ltd
14.14.1 Key Facts
14.14.2 Business Description
14.14.3 Products and Services
14.14.4 Financial Overview
14.14.5 SWOT Analysis
14.14.6 Key Developments
14.15 ADC Therapeutics SA
14.15.1 Key Facts
14.15.2 Business Description
14.15.3 Products and Services
14.15.4 Financial Overview
14.15.5 SWOT Analysis
14.15.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTIBODY DRUG CONJUGATES MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Ecosystem Analysis
4.2.1 Raw Materials and Sourcing
4.2.2 Manufacturing Processes
4.2.3 Regulatory Compliance
4.2.4 Distribution and Logistics
4.2.5 List of Vendors in the Value Chain
5. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTIBODY DRUG CONJUGATES MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
6.2 North America Antibody Drug Conjugates Market Forecast and Analysis
7. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TECHNOLOGY
7.1 Cleavable Linker
7.1.1 Overview
7.1.2 Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Non-cleavable Linker
7.2.1 Overview
7.2.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY APPLICATION
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Brain Cancer
8.2.1 Overview
8.2.2 Brain Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Ovarian Cancer
8.4.1 Overview
8.4.2 Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Lung Cancer
8.5.1 Overview
8.5.2 Lung Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TARGET
9.1 HER2
9.1.1 Overview
9.1.2 HER2: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 CD22
9.2.1 Overview
9.2.2 CD22: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 CD30
9.3.1 Overview
9.3.2 CD30: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
10.1 Retail Pharmacies
10.1.1 Overview
10.1.2 Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Hospital Pharmacies
10.2.1 Overview
10.2.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET - COUNTRY ANALYSIS
11.1 North America
11.1.1 North America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.1.1 North America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.2.2 United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 United States: North America Antibody Drug Conjugates Market Share - by Technology
11.1.2.2.2 United States: North America Antibody Drug Conjugates Market Share - by Application
11.1.2.2.3 United States: North America Antibody Drug Conjugates Market Share - by Target
11.1.2.2.4 United States: North America Antibody Drug Conjugates Market Share - by Distribution Channel
11.2.3.3 Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Canada: North America Antibody Drug Conjugates Market Share - by Technology
11.2.3.3.2 Canada: North America Antibody Drug Conjugates Market Share - by Application
11.2.3.3.3 Canada: North America Antibody Drug Conjugates Market Share - by Target
11.2.3.3.4 Canada: North America Antibody Drug Conjugates Market Share - by Distribution Channel
11.3.4.4 Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Mexico: North America Antibody Drug Conjugates Market Share - by Technology
11.3.4.4.2 Mexico: North America Antibody Drug Conjugates Market Share - by Application
11.3.4.4.3 Mexico: North America Antibody Drug Conjugates Market Share - by Target
11.3.4.4.4 Mexico: North America Antibody Drug Conjugates Market Share - by Distribution Channel
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 GSK Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Co
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Astellas Pharma Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AbbVie Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Merck KGaA
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Gilead Sciences Inc
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 BioNTech SE
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
14.13 Daiichi Sankyo Co Ltd
14.13.1 Key Facts
14.13.2 Business Description
14.13.3 Products and Services
14.13.4 Financial Overview
14.13.5 SWOT Analysis
14.13.6 Key Developments
14.14 RemeGen Co Ltd
14.14.1 Key Facts
14.14.2 Business Description
14.14.3 Products and Services
14.14.4 Financial Overview
14.14.5 SWOT Analysis
14.14.6 Key Developments
14.15 ADC Therapeutics SA
14.15.1 Key Facts
14.15.2 Business Description
14.15.3 Products and Services
14.15.4 Financial Overview
14.15.5 SWOT Analysis
14.15.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. North America Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 5. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 7. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 10. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 12. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 14. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 15. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 16. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 18. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 20. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Heat Map Analysis by Key Players
Table 1. North America Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 5. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 7. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 10. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 12. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 14. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 15. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 16. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 18. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 20. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. North America Antibody Drug Conjugates Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Antibody Drug Conjugates Market
Figure 4. North America Antibody Drug Conjugates Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
Figure 7. North America Antibody Drug Conjugates Market Share (%) - by Technology, 2023 and 2031
Figure 8. Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Antibody Drug Conjugates Market Share (%) - by Application, 2023 and 2031
Figure 11. Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Brain Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Lung Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. North America Antibody Drug Conjugates Market Share (%) - by Target, 2023 and 2031
Figure 18. HER2: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. CD22: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. CD30: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. North America Antibody Drug Conjugates Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 23. Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. North America Antibody Drug Conjugates Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 27. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Company Positioning & Concentration
Figure 1. North America Antibody Drug Conjugates Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Antibody Drug Conjugates Market
Figure 4. North America Antibody Drug Conjugates Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
Figure 7. North America Antibody Drug Conjugates Market Share (%) - by Technology, 2023 and 2031
Figure 8. Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Antibody Drug Conjugates Market Share (%) - by Application, 2023 and 2031
Figure 11. Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Brain Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Lung Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. North America Antibody Drug Conjugates Market Share (%) - by Target, 2023 and 2031
Figure 18. HER2: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. CD22: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. CD30: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. North America Antibody Drug Conjugates Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 23. Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. North America Antibody Drug Conjugates Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 27. United States: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Canada: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Mexico: North America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Company Positioning & Concentration
